MX2021012120A - Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados. - Google Patents
Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados.Info
- Publication number
- MX2021012120A MX2021012120A MX2021012120A MX2021012120A MX2021012120A MX 2021012120 A MX2021012120 A MX 2021012120A MX 2021012120 A MX2021012120 A MX 2021012120A MX 2021012120 A MX2021012120 A MX 2021012120A MX 2021012120 A MX2021012120 A MX 2021012120A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- free synthesis
- methods
- cell
- ipab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona un método libre de células para sintetizar un antígeno del antígeno B del plásmido de invasión (IpaB) asociado con una bacteria Shigella que comprende la adición exógena de la proteína chaperona IpgC purificada a la mezcla de síntesis libre de células; la descripción proporciona además mutantes de antígeno IpaB que comprenden aminoácidos no naturales incorporados durante la síntesis libre de células, lo que permite la conjugación covalente a un polisacárido Shigella de antígeno O; se proporcionan además antígenos Ipa B y conjugados de estos, así como composiciones inmunogénicas preparadas con los antígenos IpaB sintetizados y conjugados de estos y métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828364P | 2019-04-02 | 2019-04-02 | |
| PCT/US2020/025384 WO2020205584A1 (en) | 2019-04-02 | 2020-03-27 | Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012120A true MX2021012120A (es) | 2021-11-03 |
Family
ID=70416548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012120A MX2021012120A (es) | 2019-04-02 | 2020-03-27 | Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220125907A1 (es) |
| EP (1) | EP3946443A1 (es) |
| JP (1) | JP2022527206A (es) |
| KR (1) | KR20210146392A (es) |
| CN (1) | CN114025789A (es) |
| AU (1) | AU2020253332A1 (es) |
| BR (1) | BR112021019826A2 (es) |
| CA (1) | CA3135489A1 (es) |
| EA (1) | EA202192401A1 (es) |
| IL (1) | IL286819A (es) |
| MA (1) | MA55528A (es) |
| MX (1) | MX2021012120A (es) |
| SG (1) | SG11202110803YA (es) |
| TW (1) | TW202102527A (es) |
| WO (1) | WO2020205584A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021329889A1 (en) * | 2020-08-19 | 2023-04-20 | Vaxcyte, Inc. | Carrier-protein polysaccharide conjugation methods |
| AU2022221621A1 (en) * | 2021-02-17 | 2023-08-17 | Vaxcyte, Inc. | Purification processes for polysaccharides and polypeptide conjugates thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163741A1 (en) | 1993-05-28 | 1994-12-08 | Steven Rosenberg | Peptide inhibitors of urokinase receptor activity |
| US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| CN1912106A (zh) * | 2005-08-09 | 2007-02-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种痢疾多价基因工程菌苗及其制备方法 |
| AU2007349883B2 (en) * | 2007-03-27 | 2013-06-27 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Artificial invaplex |
| TWI365882B (en) * | 2007-06-15 | 2012-06-11 | Univ Nat Chunghsing | Shigella ipab803 protein, producing method and coding nucleic acid thereof |
| PT2349520T (pt) | 2008-10-27 | 2016-08-16 | Glaxosmithkline Biologicals Sa | Método de purificação para hidrato de carbono de estreptococos grupo a |
| US9040253B2 (en) | 2010-04-14 | 2015-05-26 | Sutro Biopharma, Inc. | Method for enhancing recombinant protein production by cell-free protein expression system |
| US20140294930A1 (en) | 2011-08-04 | 2014-10-02 | The Regents Of The University Of California | STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
| KR102018863B1 (ko) | 2012-10-12 | 2019-09-05 | 서트로 바이오파마, 인크. | 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 |
| US9938516B2 (en) | 2013-10-11 | 2018-04-10 | Sutro Biopharma, Inc. | Non-natural amino acid tRNA synthetases for para-methylazido-L-phenylalanine |
| EP3177324A1 (en) * | 2014-08-05 | 2017-06-14 | GlaxoSmithKline Biologicals S.A. | Carrier molecule for antigens |
| CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| WO2020010000A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| WO2020010016A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
-
2020
- 2020-03-27 AU AU2020253332A patent/AU2020253332A1/en active Pending
- 2020-03-27 EA EA202192401A patent/EA202192401A1/ru unknown
- 2020-03-27 CN CN202080040388.1A patent/CN114025789A/zh active Pending
- 2020-03-27 KR KR1020217035696A patent/KR20210146392A/ko unknown
- 2020-03-27 EP EP20721034.5A patent/EP3946443A1/en active Pending
- 2020-03-27 WO PCT/US2020/025384 patent/WO2020205584A1/en unknown
- 2020-03-27 MX MX2021012120A patent/MX2021012120A/es unknown
- 2020-03-27 CA CA3135489A patent/CA3135489A1/en active Pending
- 2020-03-27 BR BR112021019826A patent/BR112021019826A2/pt unknown
- 2020-03-27 MA MA055528A patent/MA55528A/fr unknown
- 2020-03-27 JP JP2021559041A patent/JP2022527206A/ja active Pending
- 2020-03-27 TW TW109110651A patent/TW202102527A/zh unknown
- 2020-03-27 SG SG11202110803YA patent/SG11202110803YA/en unknown
-
2021
- 2021-09-29 IL IL286819A patent/IL286819A/en unknown
- 2021-10-01 US US17/492,190 patent/US20220125907A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527206A (ja) | 2022-05-31 |
| US20220125907A1 (en) | 2022-04-28 |
| WO2020205584A1 (en) | 2020-10-08 |
| KR20210146392A (ko) | 2021-12-03 |
| EP3946443A1 (en) | 2022-02-09 |
| TW202102527A (zh) | 2021-01-16 |
| IL286819A (en) | 2021-10-31 |
| CN114025789A (zh) | 2022-02-08 |
| SG11202110803YA (en) | 2021-10-28 |
| EA202192401A1 (ru) | 2022-03-30 |
| CA3135489A1 (en) | 2020-10-08 |
| MA55528A (fr) | 2022-02-09 |
| AU2020253332A1 (en) | 2021-11-25 |
| BR112021019826A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2668560C2 (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| MX2021012120A (es) | Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados. | |
| CY1108693T1 (el) | Βελτιωμενες ανοσοενισχυτικες συνθεσεις σαπωνινης και μεθοδοι οι οποιες σχετιζονται με αυτες | |
| Ding et al. | Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene | |
| ES2335557T3 (es) | Conjugados de peptido-polisacarido. | |
| TW201704464A (zh) | 包含肽袖珍基因表現系統之以李斯特菌屬為主的組成物及其使用方法 | |
| SG155777A1 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
| CY1105737T1 (el) | Εμβολιο αναλογου βητα -amyloid και επιτοπου -τ- κυτταρου | |
| WO2006083301A3 (en) | Immunogenic compositions comprising hmgb1 polypeptides | |
| RU2015112079A (ru) | Композиции и способы, имеющие отношение к мутантному токсину из Clostridium Difficile | |
| PT98380A (pt) | Processo para a preparacao de um co-conjugado compreendendo proteina imunogenica | |
| ES2542973T3 (es) | Adyuvante para vacunas, vacunas que comprenden dicho adyuvante y sus usos | |
| UY27059A1 (es) | Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos | |
| US20230233673A1 (en) | Steroid acid-based immunogen enhancers | |
| JP2023549426A (ja) | 免疫応答及び／又は安定性を改善するために共有結合で修飾された抗原 | |
| MX2021014226A (es) | Arn terapeutico para cancer de ovario. | |
| MX2023008339A (es) | Conjugados anticuerpo-fármaco de camptotecina y métodos de uso de estos. | |
| DK1272633T3 (da) | Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi | |
| KR20070122563A (ko) | 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원 | |
| ES2612945T3 (es) | Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula | |
| WO2019122050A1 (en) | Methods of immunization | |
| ES2234287T3 (es) | Vacunas que comprenden proteinas de choque termico (hsp) inducidas por citoquinas. | |
| Bagha et al. | Overexpression and purification of diphtheria fusion toxin: DAB389IL-2 | |
| JP2023516420A (ja) | がんタンパク質抗原を発現するように操作された生チフス菌ベクターおよびその使用方法 | |
| WO2007127372A3 (en) | Genetic adjuvants for viral vaccines |